Fresenius Medical Care AG
FMSFresenius Medical Care AG & Co. KGaA is a German healthcare company which provides kidney dialysis services through a network of 4,171 outpatient dialysis centers, serving 345,425 patients. The company primarily treats end-stage renal disease (ESRD), which requires patients to undergo dialysis 3 times per week for the rest of their lives.
Drugs in Pipeline
19
Phase 3 Programs
17
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
FMS Earnings Report
FQ end 2026-06 | Call: 2026-08-04 07:00:00
PA21
Chronic Kidney Disease Requiring Chronic Dialysis
Propofol
General Anesthesia
SmofKabiven extra Nitrogen
Nutrition Therapy
SmofKabiven emulsion for infusion
Parenteral Nutrition
Solution for Peritoneal Dialysis
Chronic Kidney Failure
SMOF lipid and Intralipid
Parenteral Nutrition
Difelikefalin Injection
Uremic Pruritus
Patiromer Powder for Oral Suspension (Part A)
Hyperkalemia
6 % Hydroxyethylstarch 130/0.4 = "Voluven®"
Sepsis
FKS518
Postmenopausal Osteoporosis
MSB11456
Rheumatoid Arthritis
Osvaren Granules
Hyperphosphatemia
MSB11022
Moderate to Severe Rheumatoid Arthritis
SmofKabiven Peripheral
Parenteral Feeding
6% hydroxyethyl starch 130/0.4
Hypovolemia
Humira®
Psoriasis
1: Hydroxyethyl starch 130/0.4, 6 %
Plasma Volume Substitution (Hypovolemia) Including Massive Hemorrhage
Ketosteril®
Renal Insufficiency, Chronic
Difelikefalin
Pruritus
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
PA21 | Phase 3 | Chronic Kidney Disease Requiring Chronic Dialysis | - | - |
Propofol | Phase 3 | General Anesthesia | - | - |
SmofKabiven extra Nitrogen | Phase 3 | Nutrition Therapy | - | - |
SmofKabiven emulsion for infusion | Phase 3 | Parenteral Nutrition | - | - |
Solution for Peritoneal Dialysis | Phase 3 | Chronic Kidney Failure | - | - |
SMOF lipid and Intralipid | Phase 3 | Parenteral Nutrition | - | - |
Difelikefalin Injection | Phase 3 | Uremic Pruritus | - | - |
Patiromer Powder for Oral Suspension (Part A) | Phase 3 | Hyperkalemia | - | - |
6 % Hydroxyethylstarch 130/0.4 = "Voluven®" | Phase 3 | Sepsis | - | - |
FKS518 | Phase 3 | Postmenopausal Osteoporosis | - | - |
MSB11456 | Phase 3 | Rheumatoid Arthritis | - | - |
Osvaren Granules | Phase 3 | Hyperphosphatemia | - | - |
MSB11022 | Phase 3 | Moderate to Severe Rheumatoid Arthritis | - | - |
SmofKabiven Peripheral | Phase 3 | Parenteral Feeding | - | - |
6% hydroxyethyl starch 130/0.4 | Phase 3 | Hypovolemia | - | - |
Humira® | Phase 3 | Psoriasis | - | - |
1: Hydroxyethyl starch 130/0.4, 6 % | Phase 3 | Plasma Volume Substitution (Hypovolemia) Including Massive Hemorrhage | - | - |
Ketosteril® | Phase 2 | Renal Insufficiency, Chronic | - | - |
Difelikefalin | Phase 2 | Pruritus | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Fresenius Medical Care AG's drug pipeline?→
CatalystAlert tracks 19 drug candidates in Fresenius Medical Care AG's (FMS) pipeline across Phase 3, Phase 2. Its lead program is PA21 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Fresenius Medical Care AG's next FDA catalyst?→
Fresenius Medical Care AG's (FMS) next tracked catalyst is a Earnings expected August 4, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track FMS biotech catalysts?→
Add FMS to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Fresenius Medical Care AG's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.